Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 14/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9520201 | 0.92 | FAAH (0.69) | FAAHKDM4EMAPT | |
| SCHEMBL9520911 | 0.92 | MAPT (0.63) | FAAHKDM4EMAPTCA12CA2 | |
| SCHEMBL9520617 | 0.91 | FAAH (0.55) | FAAHKDM4EMAPTCA12CA2 | |
| SCHEMBL9520601 | 0.91 | FAAH (0.62) | FAAHKDM4EMAPTCA12CA2 | |
| SCHEMBL9519747 | 0.88 | FAAH (0.65) | FAAHMAPTCA12CA2CA9 | |
| SCHEMBL10410350 | 0.87 | GAA (0.54) | FAAHKDM4EMAPT | |
| SCHEMBL6318888 | 0.84 | S1PR5 (0.53) | FAAHGRIN2B | |
| SCHEMBL6732909 | 0.84 | KDM4E (0.50) | FAAHKDM4EMAPT | |
| SCHEMBL6733582 | 0.83 | CYP3A4 (0.46) | FAAHKDM4EMAPT | |
| SCHEMBL1895069 | 0.81 | CYP2D6 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0308843-B1 | Bispidin derivatives as class III antiarrhythmics | BASF AG (DE) | 1993-12-15 | — | — | EP | claimed |
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| WO-2000077000-A9 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | WO | disclosed |
| EP-1192157-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077000-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
| EP-0308843-B1 | Bispidin derivatives as class III antiarrhythmics | BASF AG (DE) | 1993-12-15 | — | — | EP | disclosed |
| US-4959373-A | Bispidine derivatives as class III antiarrhythmic agents | BASF AKTIENGESELLSCHAFT (DE) | 1990-09-25 | — | — | US | disclosed |
| EP-0308843-A2 | Bispidin derivatives as class III antiarrhythmics | BASF Aktiengesellschaft (DE) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | FAAH 942/4885KDM4E 4541/4885MAPT 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.